In vitro screening for synergism of high-linear energy transfer 213Bi-radiotherapy with other therapeutic agents for the treatment of B-cell chronic lymphocytic leukemia

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 4, 2006, Pages 364-372

  Vandenbulcke, Katia ^a   Thierens, Hubert ^a   De Vos, Filip ^b   Philippé, Jan ^b   Offner, Fritz ^b   Janssens, Ann ^b   Apostolidis, Christos ^c   Morgenstern, Alfred ^c   Bacher, Klaus ^a   De Gelder, Virginie ^a   Dierckx, Rudi A ^b   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

213Bi; Apoptosis; B CLL; Chemotherapy; MTT; Synergism

Indexed keywords

ACTINIUM 225; BISMUTH 213; CISPLATIN; COBALT 60; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DOXORUBICIN; FLUDARABINE; FLUDARABINE PHOSPHATE; LIPOCORTIN 5; SIMVASTATIN; SYNEXIN; VINCRISTINE;

ALPHA RADIATION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COBALT THERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ALPHA PARTICLES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BISMUTH; COMBINED MODALITY THERAPY; DRUG SYNERGISM; GAMMA RAYS; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LINEAR ENERGY TRANSFER; RADIOISOTOPES;

EID: 33750632015     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.364     Document Type: Article

References (40)

1. Hennequin C, Favaudon V. Biological basis for chemoradiotherapy interactions. Eur J Cancer 2002;38:223.
2. Bartelink H, Schellens JH, Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 2002;38:216.
3. 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 1997;38:419.
4. Blumenthal R, Leone E, Goldenberg D, et al. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. Int J Cancer 2004;108:293.
5. Gold DV, Schutsky K, Modrak D, et al. Low-dose radioimmunotherapy ([90]Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929s.
6. Behr TM, Wulst E, Radetsky S, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunotherapy: Doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 1997;57:5309.
7. Remmenga S, Colcher D, Gansow O, et al. Continous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabled monoclonal antibody therapy of a human tumor xenograft. Gynecol Oncol 1994; 55:115.
8. Supiot S, Faivre-Chauvet A, Couturier O, et al. Comparison of the biologic effects of MAS and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 2002;94(Suppl 4):1202.
9. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha-particle immunotherapy for myeloid leukaemia. Blood 2002;100:1233.
10. Bethge WA, Wilbur DS, Storb R, et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRalpha-beta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003;101:5068.
11. Zhang M, Zhengsheng Y, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukaemia with the alpha-emitting radionuclide, bismuth 213. Blood 2002;100:208.
12. 213Bi-labeled anti-CD74. Nucl Med Biol 2003;30:715.
13. 225Ac-immunoconjugates. Nucl Med Commun 1995;16:468.
14. Apostolidis A, Carlos-Marquez R, Janssens W, et al. Cancer treatment using Bi-213 and Ac-225 in radioimmunotherapy. Nucl News 2001;44:29.
15. 213Bi-rituximab versus external gamma-irradiation for the treatment of B-CLL patients: Relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging 2003;30:1357.
16. International Commission on Radiation Units (ICRU) and Measurements. Stopping powers and ranges for protons and alpha particles. International Commission on Radiation Units and Measurements Report. ICRU Publication 49. Bethesda, MD, ICRU, 1993.
17. Foran J, Oscier D, Orchard J, et al. Pharmacokinetic stydy of single doses of oral fludarabine phosphate in patients with low-grade non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol 1999;17:1574.
18. Eksborg S. Pharmacokinetics of anthracyclines. Acta Oncol 1989;28:873.
19. Ferron GM, Rochdi M, Jusko WJ, et al. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996;36:874.
20. Rowinsky Ek, Donehower RC. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams-Wilkins, 1996:391.
21. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporin. Transpl Proc 2004;36(Suppl 2s):420s.
22. Monjanel-Mouterde S, Ciccolini J, Bagarry D, et al. Population pharmacokinetics of cisplatin after 120-hour infusion: Application to routine adaptive control with feedback. J Clin Pharm Ther 2003;28:109.
23. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imitinib mesylate (STI57I, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855.
24. Philippé J, Louagie H, Thierens H, et al. Quantification of apoptosis in lymphocyte subsets and effect of apoptosis on apparent expression of membrane antigens. Cytometry 1997;29:242.
25. Pickartz T, Ringel F, Wedde M, et al. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Exp Hematol 2001;29:1410.
26. Kaspers GJL, Veeman AJP, Pieters R, et al. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995;19:175
27. Hayon T, Dvilansky A, Shpilberg O, et al. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymph 2003;44:1957.
28. Gregoire V, Hittelman WN, Rosier JF, et al. Chemoradiotherapy: Radiosensitizing nucleoseide analogues (review). Oncol Rep 1999;6:949.
29. Kivekas I, Vilpo L, Vilpo J. Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukaemia. Leuk Res 2002;26:1035.
30. Vilpo JA, Koski T, Vilpo LM. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol 2000;65:370.
31. Jagetia GC, Baliga MS. Vincristine increases the genomic instability in irradiated, cultured human peripheral blood lymphocytes. Toxicil Lett 2002;126:179.
32. Sui M, Fan W. Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 2005;61:1151.
33. Wetherley-Mein G, Thomson AE, O'Connor TW, et al. Colchicine ultrasensitivity of lymphocytes in chronic lymphocytic leukaemia. Br J Haematol 1983;54:111.
34. Koski T, Aine R, Vilpo L, et al. Cyclosporin A-induced cell kill in vitro in various clinical-hematological types of B-cell chronic lymphocytic leukemia. Leuk Res 2002;24:805.
35. Schwartz SA, Hernandez A, Evers BM. The role of NF-κB/IκB proteins in cancer: Implication for novel treatment strategies. Surg Oncol 1999;8:143.
36. Zaninoni A, Imperiali FG, Pasquini C, et al. Modulation of nuclear factor-κB activity in B-chronic lymphocytic leukaemia. Exper Hematol 2003;31:185.
37. Boeckman HJ, Trego Ks, Turchi JJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res 2005;3:277.
38. Johnson TA, Press OW. Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 2000;85:104.
39. Fischer B, Benzin S, Ganansia-Leymarie V, et al. Cisplatin enhances the cytotoxicity of fast neutrons in a murine lymphoma cell line. Can J Physiol Pharmacol 2004;82:140.
40. Chapman-Shimshoni D, Yuklea M, Radnay J, et al. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exper Hematol 2003;31:779.